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Bordetella pertussis outer 
membrane vesicle vaccine confers 
equal efficacy in mice with milder 
inflammatory responses compared 
to a whole-cell vaccine
René H. M. Raeven1,2, Jolanda Brummelman3, Jeroen L. A. Pennings4, Larissa van der 
Maas1, Wichard Tilstra1, Kina Helm3, Elly van Riet1, Wim Jiskoot2, Cécile A. C. M. van Els3, 
Wanda G. H. Han3, Gideon F. A. Kersten1,2 & Bernard Metz1
The demand for improved pertussis vaccines is urgent due to the resurgence of whooping cough. 
A deeper understanding of the mode of action of pertussis vaccines is required to achieve this 
improvement. The vaccine-induced effects of a candidate outer membrane vesicle vaccine (omvPV) 
and a classical protective but reactogenic whole cell vaccine (wPV) were comprehensively compared 
in mice. The comparison revealed essential qualitative and quantitative differences with respect to 
immunogenicity and adverse effects for these vaccines. Both vaccines stimulated a mixed systemic 
Th1/Th2/Th17 response. Remarkably, omvPV evoked higher IgG levels, lower systemic pro-
inflammatory cytokine responses and enhanced splenic gene expression than wPV. The omvPV-induced 
transcriptome revealed gene signatures of the IFN-signaling pathway, anti-inflammatory signatures 
that attenuate LPS responses, anti-inflammatory metabolic signatures, and IgG responses. Upon 
intranasal challenge, both immunized groups were equally efficient in clearing Bordetella pertussis from 
the lungs. This study importantly shows that immunization with omvPV provides a milder inflammatory 
responses but with equal protection to bacterial colonization and induction of protective antibody and 
Th1/Th17 type immune responses compared to wPV. These results emphasize the potential of omvPV 
as a safe and effective next-generation pertussis vaccine.
The efficacy of pertussis vaccines on the market, whole-cell pertussis vaccine (wPV) and acellular pertussis vac-
cine (aPV), is under scrutiny because of a whooping cough resurgence despite high vaccination coverage1,2. The 
current view on immunity to Bordetella pertussis (B. pertussis) is that T-helper 1 and 17 (Th1/Th17) responses3,4 
and specific antibody responses are preferred for protection. wPV induce a predominant Th1/Th17 response4–6 
and a broad systemic antibody repertoire7, but are associated with mild adverse effects8,9. The suspected cor-
relation between wPV and serious acute neurological illness in children10,11 has finally led to the call for safer 
pertussis vaccines. This resulted in the introduction of better-defined aPVs in many countries. aPVs evoke high 
IgG1 antibody titers and mainly a Th2 response, which provides protection against disease, however, with a rel-
atively short duration. Recent findings for aPV suggest waning immunity in children12 and impaired prevention 
of transmission in baboons13. It is thought that aPV induce suboptimal antibody7 and T-cell responses14. These 
drawbacks call again for improved pertussis vaccines.
Outer membrane vesicles from B. pertussis (omvPV) are a potential vaccine candidate. The protection in mice 
induced by omvPV is comparable to that of aPV, based on lung colonization data after B. pertussis challenge15,16. 
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Nevertheless, the omvPV elicits a broader humoral immunity and T-cell response compared to aPV7,17. To 
match the high short-term efficacy and good safety profile of current aPVs, a more comprehensive insight into 
omvPV-induced responses is required to unravel the type of immunity and assist in future vaccine registration. 
To that end, an unbiased and detailed systems biology approach is desirable. The application of systems biology in 
vaccine research has provided a better understanding of immune mechanisms and has been useful for prediction 
of vaccine efficacy based on correlating biomarkers both for yellow fever and influenza18–20. Moreover, systems 
biology can serve to compare molecular signatures induced by distinct vaccines21,22 and gain insight into vaccine 
safety23. Previously we used a systems approach in mice to study B. pertussis infection-induced responses24.
Here, we implemented systems vaccinology to investigate the potency of omvPV in mice. As benchmark, 
wPV was included for its relevant immune responses. Importantly also markers for vaccine safety with respect to 
pro- and anti-inflammatory cytokine secretion and splenic transcriptome were compared. Finally, the recall of 
protective immune responses in omvPV versus wPV immunized mice after B. pertussis challenge was compared 
and related to responses in non-protected mice.
Methods
Vaccines and challenge culture. OmvPV from B. pertussis B1917 were produced as previously described25. 
For preparation of wPV, B. pertussis B1917 was heat-inactivated (30 min, 56 °C) in PBS. Both omvPV and wPV 
were diluted in PBS to a final concentration of 4 μ g total protein per immunization dose (300 μ l). Vaccine char-
acterization included particle size, protein composition, and LPS and DNA content7. For the challenge culture, 
stock suspension of B. pertussis strain B1917 was diluted in Verweij medium (BBio, Bilthoven, The Netherlands) 
to a final concentration of 5 × 106 colony-forming units (cfu)/ml.
Animal experiment. An independent ethical committee of the Institute for Translational Vaccinology 
(Intravacc) approved the animal experiment with identifier 201200073. Animal handling in this study was 
carried out in accordance with relevant Dutch national legislation, including the 1997 Dutch Act on Animal 
Experimentation. 8-week old female BALB/c mice (Harlan, The Netherlands) were immunized subcutane-
ously on day 0 (left groin) and day 28 (right groin) with 4 μ g total protein of either omvPV or wPV resulting in 
omvPV-immunized mice (omvPV-mice) and wPV-immunized mice (wPV-mice). Mice were challenged intrana-
sally under anesthesia (isoflurane/oxygen) with 2 × 105 cfu B. pertussis B1917 in 40 μ L Verweij medium on day 56. 
Non-immunized mice (N.I.-mice) were used as a control.
For the determination of gene expression in spleen, cytokine responses and antibody responses, mice (n = 4) 
were sacrificed on day 28 after primary immunization. In addition, mice (n = 4) were euthanized after booster 
immunization on day 28 + 4 hours (day 28(4 h)), and day 29, 30, 32, 35, 38, 42, 49 and 56. Finally, mice (n = 4 per 
group) were sacrificed 4 hours after challenge and on day 58, 63, 70, and 77 to measure bacterial load in the res-
piratory tract, antibody responses and cytokine responses. For the investigation of Th subsets, mice (n = 4) were 
sacrificed on day 49 and 77. Naive mice (n = 4) were included as additional control group on each time point. 
Mice were bled under anesthesia (isoflurane/oxygen) by orbital bleeding and sacrificed by cervical dislocation for 
further sample collection. An overview of the study design is depicted in Fig. 1.
Sample collection and preparation. For investigation of cytokine and antibody responses in serum, 
whole blood from each mouse was collected in a blood collection tube (MiniCollect 0.8 ml Z Serum Sep GOLD, 
Greiner Bio-One, Austria). After coagulation (10 min. at room temperature) and centrifugation (10 min., 3000 g), 
sera were taken and stored at − 80 °C. For the colonization assay, the right lung lobe was placed in 900 ml Verweij 
medium at room temperature. To determine pulmonary cytokine and antibody responses, the lung lysates used 
for colonization assays were filtered (Millex GV Filter unit 0.22 μ m, Millipore) and stored at − 80 °C. For char-
acterization of pulmonary gene expression, the left lung lobe was placed in 1 ml RNAlater (Qiagen), incubated 
overnight at 4 °C, and stored at − 80 °C. In addition, the spleen was excised and divided in two equal parts. For 
gene expression analysis, one piece was placed in 1 ml RNAlater (Qiagen), incubated overnight at 4 °C and stored 
at − 80 °C. For detection of Gr1+ cells, the other piece was placed in in 5 ml RPMI-1640 medium (Gibco) sup-
plemented with 10% FCS (Hyclone), 100 units penicillin, 100 units streptomycin, and 2.92 mg/ml L-glutamine 
(Invitrogen), hereafter called RPMI complete medium, and kept on ice. For the analysis of Th responses, the 
whole spleen was placed in 5 ml of RPMI medium and kept on ice. Splenocytes were isolated by homogenization 
of spleens using a 70-μ m cell strainer (BD Falcon, BD Biosciences) in RPMI complete medium.
Colonization assay. The numbers of cfu in lung tissue were determined as previously described24.
RNA isolation and microarray analysis. RNA isolation from lung and spleen tissue and a RNA quality 
check (concentration and integrity) were performed as described before24. Microarray analysis was performed 
on RNA concentrates from spleen tissue of each omvPV-mice and wPV-mice (n = 3) sacrificed at 16 time points: 
D0, D28, D28(4 h), D29, D30, D31, D32, D35, D42, D49, D56, D56(4 h), D58, D63, D70 and D77 (Fig. 1). For 
microarray analysis on lung tissue, RNA samples were analyzed obtained from individual mice sacrificed at time 
points: D56, D56(4 h), D58, D63, D70 and D77. RNA samples extracted from lung and spleen tissue of N.I.-mice 
were pooled (n = 3) for according time points described before. Amplification, labeling and hybridization of 
RNA samples for either lung or spleen tissue to microarray chips (NimbleGen 126135 k Mus musculus, Roche, 
Germany) was carried out at the Microarray Department of the University of Amsterdam, The Netherlands, as 
described previously24.
Data analysis of gene expression. Quality control and normalization of raw microarray data was per-
formed as described before24. To identify differentially expressed genes (DEGs) between experimental groups 
(naive and various time points post immunization or challenge) an ANOVA was applied. The induction or 
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repression of individual genes was expressed as fold ratio (FR) by comparing mean gene expression levels of 
experimental groups to the naive mice. Average normalized gene expression levels contain data of three mice per 
immunized group. The data of challenged non-immunized mice are individual samples of pooled RNA of three 
mice. The dataset of challenged non-immunized mice (n = 3) of our previous study24 was incorporated in the 
analysis to increase the statistical power. Probes were considered differentially expressed if they met the following 
two criteria: (i) a p-value < 0.001 (ANOVA), which corresponds to a Benjamini-Hochberg False discovery rate 
(FDR)26 of < 5%; and (ii) an absolute FR ≥ 1.5 (experimental groups compared to naive mice) for at least one time 
point. If multiple probes corresponding to the same gene were differentially expressed, their data were averaged 
to remove redundancy for further analysis. GeneMaths XT (Applied Maths, St-Martens-Latem, Belgium) was 
used to visualize differences in gene expression in heatmaps and perform the hierarchical clustering based on 
Euclidean distance (linear scaling) with UPGMA. Genes were arranged according to similar expression patterns 
in time at which genes exceeded the FR cut-off of 1.5. To facilitate visual interpretation of heatmaps, only induc-
tion (red) and repression (green) of gene expression levels with fold ratios ≥ 1.5 are visualized, therefore present-
ing fold ratios ≤ 1.5 as naive level (black). Functional enrichment with an over-representation analysis (ORA) 
based on Gene Ontology Biological Processes (GO-BP) and Kyoto Encyclopedia of Genes and Genomes (KEGG) 
by using DAVID and the detection of cell-specific or tissue-specific gene expression based on BioGPS datasets 
was performed as described previously24. Involvement of type I and II IFN-signaling pathway was performed by 
using the Interferome database (http://www.interferome.org/interferome/home.jspx)27. Additional text mining 
on gene function was performed in PubMed.
Multiplex immunoassay (MIA) and ELISA for antibody response. Levels of pulmonary IgA and 
serum IgM, IgA, total IgG and IgG subclasses (IgG1, IgG2a, IgG2b and IgG3) specific for B. pertussis antigens 
pertussis toxin (Ptx), filamentous hemagglutinin (FHA), pertactin (Prn), combined fimbria type 2 and 3 antigens 
(Fim2/3) and outer membrane vesicles B1917 (OMV B1917) were determined as described previously24 and data 
are presented in fluorescent intensity units (F.I.). Whole-cell B. pertussis ELISA to quantify total serum IgG was 
performed as described before24.
Immunoproteomic profiling of serum IgG antibodies. Antigen specificity of B. pertussis-specific 
serum IgG antibody responses were determined by SDS-PAGE and subsequent Western blotting as described 
before7.
Gr1+ cells in the spleen. The percentage of Gr1+ cells in the spleen was determined with flow cytometry as 
described before24.
Isolation and in vitro restimulation of splenocytes. After treatment with erythrocyte lysis buffer, 
splenocytes were cultured in 24-well plates at 6 × 106cells/well for 7 days at 37 °C in a humidified atmosphere 
Figure 1. Study design of the systems approach on omvPV- and wPV-induced responses. BALB/c mice 
were subcutaneously immunized with 4 μ g omvPV (red) or wPV (blue) on day 0 and day 28. Subsequently, 
the vaccine-induced responses of both vaccines were characterized over a period of 56 days at 10 different 
time points. Additionally, an intranasal B. pertussis challenge (2 × 105 cfu/mouse) was performed on day 56 in 
immunized groups and in non-immunized mice (green). Both vaccine- and infection-induced responses were 
characterized at a transcriptomic, proteomic and cellular level on given time points as depicted.
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containing 5% CO2 in IMDM medium (Gibco) supplemented with 8% FCS, 100 units penicillin, 100 units strep-
tomycin, 2.92 mg/ml L-glutamine, and 20 μ M β -mercaptoethanol (Sigma). The cells were either left unstimulated 
(medium control) or stimulated with 1 μ g/ml Prn, 1 μ g/ml Ptx, 1 μ g/ml FHA, 5 μ g/ml OMV, or 5 μ g/ml heat-killed 
B. pertussis. On day 7, supernatant was collected for cytokine analysis.
Cytokine profiling using multiplex technology. Concentrations (pg/ml) of 32 cytokines (Eotaxin, 
G-CSF, GM-CSF, IFNγ , IL-10, IL-12 (p40), IL-12 (p70), IL-13, IL-15, IL-17A, IL- 1α , IL-1β , IL-2, IL-3, IL-4, IL-5, 
IL-6, IL-7, IL-9, IP-10, KC, LIF, LIX, M-CSF, MCP-1, MIG, MIP-1α , MIP-1β , MIP-2, RANTES, TNFα , VEGF) 
present in serum and lung lysates were determined using a MIA (Milliplex MAP Mouse Cytokine/Chemokine - 
Premixed 32 Plex; Merck KGaA, Darmstadt, Germany) following the manufacturer’s protocol.
The concentration of various Th cytokines (IL-4, IL-5, IL-10, IL-13, IL-17A, TNFα , and IFNγ ) was determined 
in culture supernatant using a Milliplex mouse cytokine 7-plex luminex kit (Millipore), according to the manu-
facturer’s protocol. Measurements and data analysis were performed with Bio-Plex 200, using Bio-PlexManager 
software (version 5.0, Bio-Rad Laboratories). Results were corrected for the background (medium control) and 
cytokine concentrations were calculated and provided in pg/ml.
Statistical analysis. Data of the antibody, cytokine, and colonization assays were log-transformed after 
which a t-test was performed. p-values ≤ 0.05 were considered to indicate significant differences.
Results
OmvPV provides equal protection as wPV against B. pertussis challenge. The composition of 
both omvPV and wPV, in terms of proteins, DNA, and LPS7, was determined before mice were immunized twice 
with a four-week interval (Fig. 1). Vaccine efficacy was assessed by determining lung colonization upon an intra-
nasal B. pertussis challenge (Fig. 2A). N.I.-mice showed extensive colonization and lungs were not cleared at 
day 77 (21 days post challenge) as observed before24, whereas lungs of immunized mice were cleared faster. The 
clearance of lungs was not significantly different between omvPV-mice and wPV-mice, although the lungs of 
omvPV-mice tended to be cleared slightly faster than of wPV-mice.
Immunization with omvPV and wPV induces a mixed Th1/Th2/Th17 response. Stimulation of 
splenocytes with B. pertussis OMVs or whole-cells resulted in enhanced production of IFNγ (Th1), IL-5 and IL-13 
(Th2), IL-17A (Th17) and IL-10 in omvPV-mice and wPV-mice, compared to naive mice (Fig. 2B,C). TNFα was 
not observed, while IL-4 (Th2) was only detected after OMV stimulation in omvPV-mice. Hardly any cytokines 
were produced upon stimulation of splenocytes with the purified antigens Ptx, FHA and Prn, except for IL-17A 
after FHA stimulation in wPV-mice and IL-5 after Prn stimulation in omvPV-mice (Supplementary Fig. S1A–C, 
left panels).
OmvPV induces higher serum IgG antibody responses. OMV-specific IgM was induced by omvPV 
and at a lower rate by wPV with highest peaks at day 32 and day 49, respectively (Fig. 2D). Moderate IgG levels 
were detected 28 days after the primary immunization with either omvPV or wPV, using an anti-OMV MIA and 
a whole-cell ELISA (Fig. 2E,F). Booster immunization strongly increased IgG production in omvPV-mice and 
wPV-mice, but omvPV induced higher IgG levels than wPV. No IgG or IgM antibodies directed against purified 
antigens (Ptx, FHA, Prn, Fim2/3) were found (data not shown). The IgG subclass distribution on day 28 was 
dominated by IgG1 for both omvPV and wPV (Fig. 2G). Booster immunizations with wPV and to a much larger 
extent with omvPV stimulated IgG3 antibody production as is shown on day 56 (Fig. 2G). Most of these IgG3 
antibodies were directed against LPS7. Confirmed here, higher levels of anti-LPS IgG antibodies were detected in 
omvPV-mice compared to wPV-mice (Fig. 2H). Moreover, these anti-LPS IgG antibodies were observed solely 
on day 56, indicating that these antibodies were elicited by the booster immunization. Additionally, both vaccines 
mainly induced anti-Vag8 and anti-BrkA antibodies (Fig. 2H).
Less pro-inflammatory cytokine induction in serum by omvPV compared to wPV. Vaccine-induced 
cytokine responses in serum occurred mainly 4 hours after booster immunization (day 28(4 h)). Concentrations 
of CCL4, CXCL10, G-CSF, IL-1α , and IL-6 were significantly enhanced in omvPV-mice and wPV-mice compared 
to levels before immunization (Fig. 3). In omvPV-mice, all these cytokine concentrations were significantly lower 
than in wPV-mice. Moreover, CCL2, CXCL1, IL-1β , IL-5, and IL-13 concentrations were only significantly elicited 
in wPV-mice.
Enhanced anti-inflammatory transcriptomic profiles in the spleen after omvPV immunization. 
In total, 423 and 185 differentially expressed genes (DEGs) were identified in the spleen compared to naive mice 
(day 0) (p-value ≤ 0.001, FR ≥ 1.5) in omvPV-mice and wPV-mice, respectively (Fig. 4A). Of these DEGs, 160 
(132 upregulated, 28 downregulated) overlapped between both immunized groups. Additionally, 263 DEGs (180 
upregulated, 83 downregulated) were exclusively detected in omvPV-mice, whereas 25 DEGs (21 upregulated, 4 
downregulated) were only found in wPV-mice.
Overrepresentation analysis (ORA) gained insight into molecular pathways activated by immunization and 
revealed enrichment of 77 gene ontology biological pathways (GO-BP) terms and 2 KEGG pathways (Benjamini 
≤ 0.05) in the dataset of omvPV-mice and/or wPV-mice. The immunity-related pathways are shown in Fig. 4B. 
The terms Immune response, Defense response, and Cell cycle contained more genes upregulated in omvPV-mice 
than in wPV-mice. Both groups had an equal number of genes related to Phagocytosis and B-cell mediated 
immunity (Fig. 4B).
Genes were clustered based on (i) co-expression over time and (ii) overlap between both immunized groups 
(Fig. 4C). Additionally, the vaccine-induced response could be divided in three phases based on hierarchical 
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clustering (Supplementary Fig. S2A): early phase (D28(4 h)-D32), middle phase (D35–D42) and late phase (D49–
D56) (Fig. 4C). By gene clustering, 7 groups were identified and reviewed in-depth using text mining. The results 
are described in the following paragraphs.
Figure 2. Lung colonization and vaccine-induced adaptive responses in omvPV- and wPV-immunized 
mice. (A) The number of B. pertussis cfu in 1 ml challenge culture (c.c.) was confirmed before challenge. 
Subsequently, the cfu/ml in the lungs of mice was determined 4 hours and 2, 7, 14, and 21 days after challenge 
(D56(4 h)-D77). * and **p ≤ 0.05 and p ≤ 0.01 for immunized group vs. non-immunized group. (B,C) 
Splenocytes were obtained post booster immunization (day 49) of mice that were naive (black), omvPV-
immunized (red), or wPV-immunized (blue). Cytokine concentrations were determined in the culture 
supernatants after 7 days of stimulation with (B) 5 μ g/ml OMVs or (C) 5 μ g/ml B. pertussis whole-cells. Results 
for each mouse are corrected for medium stimulation. Data presented as mean ± SD (n = 4). *p ≤ 0.05 for 
immunized group vs. naive group. (D–H) The kinetics of serum (D) anti-OMV IgM, (E) anti-OMV IgG and  
(F) anti-B. pertussis IgG formation was determined for a period of 56 days after omvPV and wPV 
immunization. Data are presented as mean ± SD (n = 4). For (D) *, **, *** and ****p ≤ 0.05, p ≤ 0.01, p ≤ 0.001 
and p ≤ 0.0001 for day 28–56 vs. naive, # and ## p ≤ 0.05 and p ≤ 0.01, for D28(4 h)-D56 vs. D28, + and ++p ≤ 0.05 
and p ≤ 0.01 for omvPV-mice vs. wPV-mice. For (E,F) *, **, *** and ****p ≤ 0.05, p ≤ 0.01, p ≤ 0.001 and 
p ≤ 0.0001 for naive vs. D28, #, ##, ### and ####p ≤ 0.05, p ≤ 0.01, p ≤ 0.001 and p ≤ 0.0001 for D28 vs. D56,  
+ and ++p ≤ 0.05 and p ≤ 0.01 for omvPV-mice vs. wPV-mice. The significance in (E) and (F) between D28(4 h)-
D49 is not depicted. (G) Subclass distribution was determined at day 56 in serum of mice immunized with 
omvPV or wPV by calculating the ratio of the level for each subclass from the sum of the levels all subclasses. 
(H) To determine antigen-specificity, the immunoproteomic profiles of serum antibodies (pooled sera, n = 4) 
following primary immunization (day 28) and booster immunization (day 56) were obtained. The band 
positions of Vag8, BrkA and LPS antigens are indicated as identified previously7.
www.nature.com/scientificreports/
6Scientific RepoRts | 6:38240 | DOI: 10.1038/srep38240
Group 1 consists of DEGs that were exclusively expressed in the early phase of the omvPV-induced response. 
This group comprised genes related to pathogen recognition, such as Fpr1 and genes related to Toll-like receptor 
(TLR) 3 (Tlr3, Mlkl) and TLR7 (Tlr7, Treml4, Lgmn, Trex1) mediated signaling. Trex1 limits pro-inflammatory 
signals following TLR7 activation in macrophages28, whereas Siglece represses TLR-signaling in general29. 
Moreover, IL-1 receptor antagonist (Il1rn) and members of the Bcl-family, (Bcl2a1a, Bcl2a1b, Bcl2a1c, Bcl2a1d, 
Bcl3), paired-Ig-like receptors (Pira1, Pira2, Pira4, Pira6, Pira11, Lilrb3), and IFN-induced transmembrane 
proteins (Ifitm1, Ifitm2) were detected. Genes related to processing of LPS included Bst2, Eif2ak2, essential for 
LPS-induced iNOS production30, and Msr1 that inhibits LPS-stimulated IL-6 secretion31.
Group 2 genes were exclusively upregulated in the middle phase of the omvPV-induced response. This group 
contained genes related to myeloid cells (Mcpt8, Clec12a, Chi3l3) and more specifically neutrophils (Cd177, 
Cebpe, Clec1b, Elane, Lcn2, Ltf, Ngp).
Group 3 includes antibody-related genes, such as Igkc, Igj, Igk, and Ighg, which showed higher expression in 
omvPV-mice than in wPV-mice (Fig. 5A), in line with the increased antibody levels (Fig. 2D–F).
Group 4 genes were upregulated in the early phase of immunization in omvPV-mice, but were not or hardly 
upregulated in wPV-mice. Most of these genes were also differentially expressed in the middle phase. This group 
contained the anti-inflammatory Fpr232 and Steap4 that decreases inflammatory effects by repressing IL-6 produc-
tion33. Moreover, genes involved in LPS responsiveness were upregulated, such as Slpi that suppresses responses to 
LPS34, Hmox1, Stfa3, Stfa2l1, and Angptl4 that are induced by LPS in the acute phase response35. Notably, Angptl4 
has multiple functions, including inflammation and lipid metabolism36. Genes involved in metabolism (Hk3, 
Tbxas1) and more specifically the lipid metabolism (Angptl4, Lpl, Hpgds) were found in this group. Furthermore, 
this group comprised Pf4/Cxcl4, myeloid cell specific genes (Lilrb4, Ms4a3, Serpina3g), danger-associated molec-
ular patterns (DAMPs; S100a9, S100a8), IFN-induced genes (Slfn4, Ifitm6) and Fcgr4 that binds IgG2a and IgG2b. 
Moreover, neutrophil-related genes (Mpo, Prtn3, Cxcr2, Il1f9) were detected. Notably, IL-1F9 promotes Th1 for-
mation by binding IL-36R on T-cells37.
Group 5 contains genes that were expressed by both vaccines on day 29. Some of these genes are involved in 
the type I IFN-signaling pathway. This included Irf7, Oasl1, that inhibits IRF738, and other IFN-induced proteins 
(Ifi44, Ifi204, Ifi202b, Ifi27l2a, Ifit1, Ifit2, Ifit3, Ifih1, Ifitm3, Irgm1, H28, Mnda, Oasl2, Tor3a, Lgals3bp, Mx2). 
Moreover, two genes were detected that encode pathogen recognition receptors (PRRs) sensing cytosolic DNA: 
DAI (Zbp1)39 and LPG2 (Dhx58)40. Furthermore, genes encoding Fc receptors (Fcgr1, Fcer1g), a NOD-like recep-
tor and neutrophil migration marker41 (Nlrp12), C-type lectins (Clec4d, Clec4e), and other membrane mark-
ers (Ly6a, Ms4a6d, Cd300lf, Gp49a) were identified. Moreover, differential gene expression was detected for 
two genes encoding tripartite-motif proteins (Trim30a, Trim30c) of which TRIM30α inhibits TLR4-mediated 
NF-kappaB activation42.
Figure 3. Serum cytokine secretion following omvPV or wPV immunization. Concentrations of 32 cytokines 
were determined in serum at multiple time points after immunization with omvPV or wPV. Levels of CXCL10, 
G-CSF, CXCL1, IL-1α , IL-6, IL-5, IL-13, IL-1β , CCL4, and CCL2 were significantly altered and are depicted 
here. The different stages of primary immunization and booster immunization are depicted in the panels. Data 
represent mean ± SD (n = 4). *p ≤ 0.05 for immunized group vs. naive, + p ≤ 0.05 for omvPV group vs. wPV group.
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Group 6 genes were upregulated on day 28(4 h) by both vaccines. This group included an LPS-induced mac-
rophage gene (Ifi205), the inflammatory chemokine Ccl12, the interleukin 1 receptor, type II (Il1r2), and Ptpn1 
that controls pro-inflammatory responses after LPS exposure43. Moreover, genes encoding membrane mark-
ers were detected (Cd244, Cd300e, Ccr3) of which some are related to pathogen-recognition, such as dectin-2 
(Clec4n) that recognizes high-mannose ligands, and Cd14 involved in LPS binding.
Group 7 genes were merely differentially expressed in the wPV-mice. This group included genes on immune 
cells such as C4b, Cd83 an important activation marker on B-cell, T-cell, and dendritic cell populations44, Fcgr3, 
Figure 4. Transcriptomic profiles in the spleen following omvPV and wPV booster immunization.  
(A) Fold changes of DEGs were calculated compared to naive mice (FR ≥ 1.5, p-value ≤ 0.001). In total, 448 
DEGs were found divided over both vaccine responses, as depicted in a Venn-diagram with total number of 
genes (black) and both upregulated (red) and downregulated genes (green). (B) Overrepresentation analysis 
on all 448 genes revealed the involvement of specific GO-BP terms and KEGG pathways with corresponding 
upregulated (red) and downregulated (green) genes. (C) All differentially upregulated (red) and downregulated 
(green) genes are portrayed as heatmap (mean of n = 4). Genes not surpassing a FR of 1.5 are shown as basal 
level (black) at this time point. Gene clustering is based on up/downregulation, time of involvement, and 
presence in the immunization group. The overlap and the exclusive presence of DEGs in either the omvPV or 
wPV groups are further depicted next to the heatmap. Booster immunization-induced responses were divided 
in three phases: early phase (D28(4 h)-D32), middle phase (D35-D42) and late phase (D49-D56) as calculated in 
Supplementary Fig. S2A. Selections of genes co-expressed in seven (1–7) areas of the heatmap are shown.
www.nature.com/scientificreports/
8Scientific RepoRts | 6:38240 | DOI: 10.1038/srep38240
Ighm, Irf9, Ly6e, and Parp14. PARP-14 promotes Th2 and Th17 cell formation and steers the antibody subclass 
distribution45,46.
Based on this text mining, sets of genes involved in antibody formation, PRRs, interferon regulatory fac-
tors (IRFs), IL-1 signaling, LPS sensing and lipid metabolism were found (Fig. 5). Subsequently, the dataset was 
matched with the Interferome database to identify which vaccine-induced genes were involved in the type I 
and type II IFN-signaling pathways (Supplementary Fig. S3). In total, 91 genes were related to type I IFN, 22 to 
type II IFN, and 60 genes to both pathways. The majority of IFN-related genes of both type I and II were induced 
by omvPV, whereas only 13 genes were found exclusively in wPV-mice. Moreover, the type II IFN-signaling path-
way was mainly involved in the early phase. The type I IFN-signaling pathway genes were also mainly found in 
the early phase, but also partly in later phases (Supplementary Fig. S3).
Higher neutrophil responses elicited by omvPV compared to wPV. Transcriptome com-
parison with BioGPS databases particularly revealed involvement of MAC+GR1+ granulocytes (neutro-
phils) in vaccine-induced immune responses (Supplementary Fig. S4A). These 46 genes were all detected 
in omvPV-mice and mainly activated during the early and middle phase of the vaccine-induced response 
(Supplementary Fig. S4B). In contrast, only 16 of these 46 genes were upregulated in wPV-mice. Flow cytometry 
confirmed that the percentage of Gr1+ cells in the spleen was significantly increased by omvPV and wPV immu-
nization between days 29–42 (Supplementary Fig. S4C). In line with the enhanced gene expression, a significant 
higher number of Gr1+ cells was detected in the middle phase (day 42) in omvPV-mice compared to wPV-mice.
Immunized mice showed reduced serum and pulmonary cytokine responses following B. pertussis 
challenge. Subsequent to the investigation of vaccine-induced responses, we examined the immune 
responses after B. pertussis challenge (Fig. 1). First, concentrations of 32 cytokines were determined in serum 
and lung lysate (Fig. 6A,B). In sera of N.I.-mice, IL-1α , IL-1β , CXCL2, CCL3, IL-13, and G-CSF were signifi-
cantly increased mainly between days 63–77. Notably, no significant serum cytokine secretion was observed in 
omvPV-mice (Fig. 6A). Serum concentrations of IL-1α , IL-1β , IL-5, IL-6, IL-10, IL-12(p70), IL-13, CCL3, CCL4, 
CCL5, CXCL1, CXCL2, and CXCL10 were significantly higher in wPV-mice compared to omvPV-mice, mainly 
on day 63. However, the B. pertussis challenge did not lead to significant induction of cytokine levels compared to 
day 56 in wPV-mice, except for CCL3 (Fig. 6A). In the lungs, IL-17A, G-CSF, CXCL9, CCL4, and CXCL10 were 
Figure 5. Selected splenic transcriptome profiles following omvPV and wPV booster immunization. The 
splenic transcriptome profiles of genes related to antibodies, pathogen recognition receptors (PRRs), interferon 
regulatory factors (IRFs), IL-1 signaling, LPS sensing, and lipid metabolism are depicted.
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significantly increased in N.I.-mice, between day 63–77 whereas these cytokines were not elevated in either of the 
immunized groups, except for G-CSF in wPV-mice between day 56(4 h)-63 (Fig. 6B).
Reduced transcriptomic profiles in the spleen of immunized mice following B. pertussis challenge. 
In total, 402 DEGs (p-value ≤ 0.001, FR ≥ 1.5) were detected in the spleen of immunized mice or N.I.-mice 
after B. pertussis challenge (Fig. 7A). This analysis demonstrated less intense gene expression profiles in 
omvPV-mice and wPV-mice than in N.I.-mice following the challenge with B. pertussis. These responses were 
even lower in omvPV-mice compared to wPV-mice. 87, 7, and 59 DEGs were exclusively detected in the chal-
lenged omvPV-mice, wPV-mice, and N.I.-mice, respectively. 120 DEGs (70 upregulated, 50 downregulated) 
were found in all three groups (Fig. 7A). The ORA on infection-induced responses in the spleen revealed 
enrichment of 24 GO-BP terms and 2 KEGG pathways (Benjamini ≤ 0.05) in omvPV-mice, wPV-mice, and 
N.I.-mice (Fig. 7B). In omvPV-mice, several downregulated genes are involved in Cell cycle (33 genes) and Cell 
division (18 genes). The terms Immune response and Defense response comprised a smaller number of genes 
in omvPV-mice than in wPV-mice and N.I.-mice. Genes were clustered based on (i) co-expression over time 
and (ii) overlap between both experimental groups (Fig. 7C). Hierarchical clustering on the three challenged 
groups indicated that infection-induced responses were distinct in immunized mice compared to the challenged 
Figure 6. Serum and pulmonary cytokine secretion following B. pertussis challenge in mice immunized 
with omvPV or wPV and non-immunized mice. (A,B) The concentrations of 32 cytokines were determined 
prior to and at multiple time points post challenge with B. pertussis in non-immunized mice (green) or mice 
immunized with omvPV (red) or wPV (blue). Only cytokines that were significantly altered in (A) serum 
and (B) lung lysate are depicted. Data are presented as mean ± SD for immunized groups (n = 4) and non-
immunized groups (n = 3). *p ≤ 0.05 for challenged groups vs. day 56, #p ≤ 0.05 for immunized groups vs. non-
immunized group, +p ≤ 0.05 for omvPV group vs. wPV group.
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N.I.-mice (Supplementary Fig. S2B). The infection-induced response of N.I.-mice was divided in three phases: 
early phase (D56(4 h)-D58), middle phase (D63), and late phase (D70–D77). In omvPV-mice, the response 
Figure 7. Transcriptomic profiles in the spleen following B. pertussis challenge in omvPV-, wPV-, and non-
immunized mice. (A) Fold changes in expression and significant gene expression were calculated compared 
to naive mice (FR ≥ 1.5, p-value ≤ 0.001). In total, 402 DEGs were found divided over the three groups in a 
Venn-diagram with total number of genes (black), upregulated genes (red), and downregulated genes (green). 
(B) Overrepresentation analysis on all 402 genes revealed the involvement of specific GO-BP terms and KEGG 
pathways with corresponding upregulated (red) and downregulated (green) genes. (C) All differentially 
upregulated (red) and downregulated (green) genes are portrayed as heatmap (mean of n = 3 for immunized 
groups, n = 1 (pool of 3 mice for non-immunized group)). Genes not surpassing a FR of 1.5 are shown as basal 
level (black). Gene clustering is based on up/downregulation, time of involvement, and presence in different 
groups. Infection-induced responses were divided in phases according to the hierarchical clustering calculated 
in Supplementary Fig. S2B. Selections of genes in nine (1–9) areas of the heatmap are shown.
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was faster compared to N.I.-mice. In wPV-mice, the response was slightly slower compared to omvPV (Fig. 7C 
and Supplementary Fig. S2B). A selection of genes involved in nine (1–9) areas is depicted in the heatmap. 
The involvement of neutrophils was more pronounced in challenged N.I.-mice as we detected 38 genes com-
monly expressed in MAC+GR1+ granulocytes compared to only 10 and 22 of these genes in omvPV-mice and 
wPV-mice, respectively (Supplementary Fig. S4D). Flow cytometry analysis confirmed a significantly increased 
number of Gr1+ cells, indicative for neutrophils, in N.I.-mice on day 70 (Supplementary Fig. S4E). This Gr1+ cell 
fraction in immunized mice was significantly lower between days 70–77 compared to N.I.-mice.
B. pertussis challenge has less impact on gene expression in the lungs of omvPV-mice than in 
wPV-mice and N.I.-mice. In total, 3269 DEGs (p-value ≤ 0.001, FR ≥ 1.5) were detected in lungs of immu-
nized mice or N.I.-mice following B. pertussis challenge (Supplementary Fig. S5A). The pulmonary transcriptome 
in omvPV-mice on day 56 prior to challenge differs a lot from the naive basal gene expression level. Compared to 
day 56, the B. pertussis challenge induced less change in pulmonary gene expression in omvPV-mice as compared to 
wPV-mice and N.I.-mice. Exclusive expression of 578, 156, and 90 DEGs was detected in challenged omvPV-mice, 
wPV-mice, and N.I.-mice, respectively. In total, 1702 DEGs (695 upregulated, 1007 downregulated) were found 
in all three groups (Supplementary Fig. S5A). Genes were clustered based on (i) co-expression over time and (ii) 
overlap between both experimental groups (Supplementary Fig. S5B). Hierarchical clustering of the pulmonary 
transcriptome of the three challenged groups demonstrated a distinct infection-induced response in immunized 
mice compared to challenged N.I.-mice (Fig. S2C). The infection-induced response of N.I.-mice was divided in 
three phases: early phase (D56(4 h)-D58), middle phase (D63 and D77) and late phase (D70), as seen before24. In 
omvPV-mice, the response was less diverse compared to day 56 and divided in two phases; early phase (D56(4 h)) 
and middle phase (D70). In wPV-mice, the response compared to day 56 was more diverse and developed slower 
than in omvPV-mice with an early phase (D63–D70) and middle phase (D77) (Supplementay Figs S2C and S5B).
Adaptive recall responses in omvPV-mice and wPV-mice following B. pertussis challenge. 
Prior to the intranasal B. pertussis challenge (day 56), no vaccine-induced anti-OMV IgA was detected in the 
lungs of omvPV-mice and wPV-mice. However, similar amounts of anti-OMV IgA were detected after the chal-
lenge of wPV-mice and N.I.-mice on day 63–77, but no anti-OMV IgA was found in omvPV-mice (Fig. 8A). 
Serum IgG levels specific for pertussis OMVs or whole-cells were unaltered in wPV-mice and slightly decreased 
in omvPV-mice after the challenge, whereas IgG levels in N.I.-mice were rising between day 63–77 (Fig. 8B,C). 
The IgG antibody specificity did not change in omvPV-mice after challenge, except for the disappearance of the 
15 kDa band (Fig. 8D). The challenge of wPV-mice stimulated antibody formation against GroEL (60 kDa) and 
an unknown antigen of 20 kDa.
Regarding post challenge Th-responses, the stimulation of splenocytes with OMVs revealed altered Th1 
(TNFα ), Th2 (IL-5, IL-13), and Th17 (IL-17A) cytokines in challenged omvPV-mice, wPV-mice, and N.I.-mice 
compared to naive mice (Fig. 8E,F and Supplementary Fig. S1). IL-5 and IL-17A levels were higher in immu-
nized mice compared to N.I.-mice (Fig. 8E). Stimulation with B. pertussis whole-cells led to altered levels of Th1 
(IFNγ ), Th2 (IL-5, IL-13) and Th17 (IL-17A) cytokines in omvPV-mice, wPV-mice, and N.I.-mice compared to 
naive mice. These levels were overall higher in immunized mice compared to N.I.-mice. Moreover, IL-10 pro-
duction was only observed in immunized mice (Fig. 8F). IFNγ and TNFα were both high in naive control mice 
after stimulation with B. pertussis OMVs and whole-cells, most likely caused by LPS. Nevertheless, omvPV-mice 
and wPV-mice showed a similar result post challenge (day 77) as after immunization (day 49). Prn stimula-
tion resulted in increased IL-13 and IL-17A concentrations in all challenged mice compared to naive control 
mice (Supplementary Fig. S1A, right panel). These IL-17A levels were significantly higher in immunized mice 
compared to N.I.-mice. Furthermore, significantly higher IL-5 production was observed in omvPV-mice and 
N.I.-mice than in wPV-mice. After Ptx stimulation, IL-17A production was exclusively detected in wPV-mice 
(Supplementary Fig. S1B, right panel). IL-5, IL-13 and IL-17A production was evoked by FHA stimulation 
in immunized and N.I.-mice. Moreover, enhancement of IFNγ , TNFα , and IL-10 was detected in wPV-mice 
(Supplementary Fig. S1C, right panel). Overall enhanced Th1/Th2/Th17 ex vivo recall responses were detected in 
challenged omvPV-mice and wPV-mice compared to challenged N.I.-mice.
Discussion
Introduction of an improved next-generation pertussis vaccine requires in-depth knowledge on vaccine-induced 
responses in comparison to current pertussis vaccines especially in terms of efficacy and safety. Parenteral injec-
tion of classical whole-cell pertussis vaccine (wPV) has been related to adverse effects8,9 and suspected of being 
correlated with serious acute neurological illness in children10,11 mainly caused by circulating pro-inflammatory 
cytokines such as IL-1β , TNFα , and IL-611,47. The adverse effects have been key reasons for the development 
of aPVs, which have a better safety profile. Our current in vivo study demonstrated that immunization with 
an OMV-based pertussis vaccine (omvPV) in comparison to wPV elicited reduced concentrations of serum 
pro-inflammatory cytokines (IL-1α , IL-1β , and IL-6), chemokines (CXCL1 and CXCL10), and G-CSF. Especially, 
reduced IL-1β secretion by omvPV may be beneficial, because IL-1β is related to acute neurological illness11. 
Although data obtained in mice may not be representative for humans, it was previously demonstrated with a 
human whole-blood stimulation assay that omvPV induces less IL-6 compared to wPV17, which is in line with 
the mouse data presented here. Other cytokines that were detected in the current in vivo mouse model could 
be investigated in a similar way or in future human clinical trials with omvPV. Activation of Toll-like receptors 
(TLRs)48 by pathogen-associated molecular patterns (PAMPs), like lipopolysaccharide (LPS) and bacterial DNA, 
result in the secretion of these cytokines. Previously we showed that omvPV contain less TLR-activating LPS 
(1.0 μ g versus 1.5 μ g) and DNA (0.2 μ g versus 1.2 μ g) than wPV7. Lower LPS and DNA concentrations in omvPV 
may induce less TLR4 and TLR9 activation and subsequently contribute to attenuated pro-inflammatory cytokine 
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response by omvPV compared to wPV. Adsorption of LPS to aluminum hydroxide causes less pro-inflammatory 
cytokine production49, which demonstrates that free LPS might be more pyrogenic than bound LPS. OmvPV may 
contain less free LPS compared to wPV thus resulting in lower cytokine induction.
Unexpectedly, in light of the attenuated pro-inflammatory cytokine signatures, omvPV immunization 
induced a larger number of genes than wPV. Yet triggering of anti-inflammatory responses, diminished PRR 
responses, and expression of modifiers that dampen inflammatory LPS responses was more prominent in 
omvPV-mice than in wPV-mice and likely explains why omvPV elicited lower amounts of pro-inflammatory 
cytokines. The omvPV-activated genes encoding anti-inflammatory PRRs FPR1 and FPR2 that bind many differ-
ent signal peptides of bacteria50 and are important for rapid neutrophil recruitment51. Furthermore, the involve-
ment of omvPV-induced genes encoding FPR2, SPLI, STEAP4, PTPN1, and MSR1, which are attenuators of LPS 
responses31–34,43, may assist in repressing LPS-induced pro-inflammation. The more prominent anti-inflammatory 
response following omvPV immunization was strengthened by activation of genes encoding proteins with a dual 
function in lipid metabolism and anti-inflammation, namely ANGPTL435,36, HPGD2S52, and LXRα . These genes 
may have been activated by lipid mediators that were released during the omvPV-induced response, which needs 
to be further investigated.
Only omvPV immunization enhances gene expression of TLR3 and TLR7, which are intracellular sensors for 
viral and bacterial nucleotides. Activation of TLRs leads to induction of IFN-signaling pathways. For instance, 
Figure 8. Humoral and cellular adaptive recall responses following B. pertussis challenge in omvPV- 
and wPV-immunized mice as compared to control mice before and after challenge. (A–C) Kinetics of 
(A) pulmonary anti-OMV IgA, (B) serum anti-B. pertussis IgG, and (C) serum anti-OMV IgG levels were 
determined for a period of 21 days following intranasal challenge in immunized mice (n = 4) and non-
immunized mice (N.I.) (n = 3). Data are presented as mean ± SD. Statistical significance of differences in (A), 
(B) and (C): *, **, *** and ****p ≤ 0.05, p ≤ 0.01, p ≤ 0.001 and p ≤ 0.0001 for vs. D56 per group, + and ++p ≤ 0.05 
and p ≤ 0.01 for omvPV vs. wPV, #, ##, ### and ####p ≤ 0.05, p ≤ 0.01, p ≤ 0.001 and p ≤ 0.0001 for immunized 
groups vs. non-immunized group. (D) Immunoproteomic profiles of serum IgG antibodies (pooled sera, 
n = 4) before (D56) and 21 days post challenge (D77) were obtained on a B. pertussis lysate. (E,F) Cytokine 
concentrations were determined in the culture supernatants after 7 day stimulation with (E) 5 μ g/ml OMVs, 
or (F) 5 μ g/ml B. pertussis whole-cells. Splenocytes were obtained from naive mice (black) and post-challenge 
(D77) of mice that were omvPV- (red), wPV- (blue) or non-immunized (green). Results for each mouse are 
corrected for medium stimulation. Data in (E) and (F) presented as mean ± SD (n = 4). Statistical significance of 
differences in (E) and (F) *p ≤ 0.05 for challenged groups vs. naive, +p ≤ 0.05 for omvPV group vs. wPV group, 
#p ≤ 0.05 for immunized group vs. non-immunized group.
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IRF7, a factor downstream of TLR7 and important mediator of type I IFN-signaling53, was induced by both 
vaccines. Overall, a large number of genes of the type I IFN-signaling and type II IFN-signaling pathway were 
induced by both vaccines but were more profound in the omvPV response. Type I IFN-signaling can affect both 
innate and adaptive immune cells54 and with respect to CD4+ T-cells, the pathway is important for the regulation 
of Th1 and Th17 responses55. Whether there are more TLR3 and TLR7 ligands present in omvPV compared to 
wPV remains to be investigated.
In addition, TLR4 activation by LPS can direct the cellular responses towards Th1 and Th17 responses5,6. Thus, 
it is important to evaluate whether the reduced TLR4-signaling by omvPV does not affect its ability to induce 
B. pertussis specific Th1 and Th17 responses. Cytokine profiles of stimulated splenocytes revealed that omvPV 
and wPV both induce mixed systemic Th1/Th2/Th17 responses, in contrast to the Th2-biased aPV-induced 
response4,14. This indicates that despite lower LPS concentration and TLR4-signaling, omvPV still induced a 
similar Th response as wPV. This may suggest that the LPS concentration in omvPV is sufficient for the induction 
of Th1/Th17 responses or that other signaling pathways, such as via TLR2 through lipoproteins56,57, also promote 
Th17 responses. Induction of both types of IFN-signaling pathways by omvPV and wPV may contribute to these 
Th1/Th17 responses that are thought to be important for protection3,4,24.
The omvPV and wPV used in this study contain low concentrations of aPV components (Prn, FHA, and Ptx). 
except for FHA in wPV7, which also resulted in low antibody and T-cell responses specific for these antigens fol-
lowing immunization. However, high antibody levels against other B. pertussis-specific antigens such as BrkA, 
Vag8 and LPS, were detected. These antibodies were especially formed after booster immunization and overall 
higher in omvPV-mice. The omvPV also contains higher concentrations of BrkA and Vag87. As Prn-deficient B. 
pertussis strains are increasingly circulating, especially in aPV-immunized populations, it has been hypothesized 
that this might be the result of pathogen adaptation58,59. Therefore, the broad humoral response conferred by both 
omvPV and wPV might limit the risk of driving B. pertussis adaptation caused by vaccine-induced selection pres-
sure. Remarkably, despite lower LPS concentrations in omvPV, the booster omvPV immunization induced higher 
anti-LPS IgG3 antibody levels than wPV7. This indicates that the LPS in omvPV was processed in a different way by 
the immune system during the first immunization compared to booster immunization. Since anti-LPS IgG3 anti-
bodies are mostly produced in a T-cell independent manner60, this may indicate that omvPV evokes a more efficient 
T-cell independent B-cell response than wPV. Furthermore, mucosal B. pertussis-specific IgA induction in the lungs 
was absent after omvPV and wPV immunization, as expected. Mucosal IgA is produced after natural infection24 
and contributes most likely to a faster lung clearance during B. pertussis challenge. Presumably, direct involvement 
of the respiratory tract through mucosal vaccine administration may result in more effective immunity.
Immunization with omvPV or wPV enabled rapid clearance of B. pertussis from the lungs after challenge 
when compared to N.I.-mice. Whereas no significant differences in lung clearance were observed between both 
immunized groups, the lungs of omvPV-mice tended to be cleared slightly faster perhaps because of the higher 
serum IgG levels. Previously, intraperitoneal immunization with alum-adjuvated omvPV and wPV derived 
from a B. pertussis Tohama strain also demonstrated equal protection15. The B. pertussis challenge elucidated 
the pre-existing immunity in omvPV-mice and wPV-mice. The immune responses of challenged immunized 
mice were characterized by (i) adaptive recall responses, (ii) a change in pulmonary environment by reduced 
cytokine secretion and transcriptome expression, (iii) altered systemic cytokine responses, and (iv) reduced 
splenic transcriptome expression in comparison to challenged N.I.-mice. The presence of high serum IgG levels 
and strong recall of Th1/Th2/Th17 responses enabled a rapid clearance in both immunized groups. In contrast 
to vaccine-induced responses, the challenge-induced responses revealed specific T-cell activation against puri-
fied proteins FHA, Prn and Ptx as a result of prolonged exposure to these antigens after B. pertussis challenge24. 
Furthermore, immunized mice responded less vigorously to an infection with respect to transcriptome, cytokine 
responses and number of splenic neutrophils. In line with our previous study24, N.I.-mice showed the largest 
changes in gene expression in the lungs 14 days after challenge, whereas these responses were overall lower in 
omvPV-mice than wPV-mice. Overall, B. pertussis challenge-induced responses in wPV-mice resembled those 
of N.I.-mice more than those of omvPV-mice, which may indicate that the B. pertussis challenge was controlled 
more effectively in omvPV-mice than wPV-mice. For instance, challenged omvPV-mice revealed no presence of 
antigen-specific IgA in the lungs nor IL-17A secretion after ex vivo Ptx stimulation of splenocytes, while these 
responses appeared in both wPV-mice and N.I.-mice. Therefore, the B. pertussis exposure in wPV-mice may have 
been longer than in omvPV-mice as this Ptx exposure only occurs during B. pertussis colonization, since Ptx is 
absent in both omvPV and wPV used in this study7.
In summary, we demonstrated that in comparison to a classical wPV, omvPV confers equal, if not more rapid 
protection with higher IgG levels and a comparable Th1/Th2/Th17 response. Additionally, the systems approach 
provided detailed insight into the molecular signatures of the vaccine as well as challenge-induced responses. 
Importantly, the inflammatory responses elicited by omvPV were milder than those by wPV, as reflected by 
reduced levels of pro-inflammatory cytokines. Probably, inflammatory responses are attenuated by the enhanced 
anti-inflammatory responses, i.e. ANGPTL4, FPR2, PTPN1, SPLI, and STEAP4. Therefore, it is tempting to spec-
ulate that the decreased inflammatory responses induced by omvPV reflect a better safety profile. In conclusion, 
our collective findings emphasize the potential of omvPV as a third-generation pertussis vaccine.
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